We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen, in an expected move, is appealing a federal judge’s decision that cleared the way for Sandoz to launch Zarxio, its biosimilar of Amgen’s chemotherapy product Neupogen. Read More
Boehringer Ingelheim and Teva are again being accused of blocking generic competition to the brandmaker’s antistroke drug Aggrenox just days after their bid to toss a similar lawsuit was denied. Read More
A federal judge has given the go-ahead to a class action lawsuit alleging Boehringer Ingelheim and Teva conspired to put off generic competition to the antistroke drug Aggrenox. Read More
The U.S. Supreme Court has declined to hear one of three petitions submitted over a Pennsylvania appellate decision refusing to recognize generic drugs as largely immune from product liability lawsuits. Read More
Generics maker Glenmark might have infringed on Merck’s Indian patent covering type II diabetes drugs Januvia and Janumet, the Delhi High Court in India said recently in an interim ruling. Read More
A federal appeals court has affirmed a lower court ruling that Allergan’s Zymar eye drop patent is invalid because the process is obvious for others to try. The decision paves the way for generic versions of the drug. Read More
The FTC signed off on a divestiture order allowing Sun Pharma’s imminent $4 billion purchase of fellow Indian generics maker Ranbaxy to go forward as long as the companies relinquish rights to the antibiotic minocycline. Read More